title: [A case of interstitial pneumonia induced by gemcitabine hydrochloride for unresectable bile duct cancer].
abstract: A 78-year-old man was admitted for obstructive jaundice and unresectable bile duct cancer on March 4, 2008. Since biliary drainage was extremely difficult, he began 2 treatment courses of gemcitabine hydrochloride (GEM 800 mg/m(2) on days 1, 8, 15 every 4 weeks). He suffered from dry cough and dyspnea on May 13, 2008. He was diagnosed as GEM-induced interstitial pneumonia with severe hypoxemia by CT scan and arterial blood gas examination. He recovered with two courses of steroid pulse therapy, diuretics and antibiotics. Alternatively, he was given oral S-1 ( 80 mg/m(2) 4 weeks on and 2 weeks off) from June 12, 2008. His QOL was well kept without jaundice for as long as a half year. This is the first report of GEM-induced interstitial pneumonia in bile duct cancer. In conclusion, interstitial pneumonia must be taken into consideration as a rare adverse reaction when GEM is used for biliary neoplasms.
authors.affiliation: Division of Gastroenterology and Hepatology, Nagaoka Red Cross Hospital.
authors.forename: Tomofumi
authors.initials: T
authors.lastname: Miura
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Suzuki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ozeki
authors.forename: Junichiro
authors.initials: J
authors.lastname: Nakamura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamada
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Miura
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yanagi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Sato
authors.forename: Toru
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000097:blood / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001663:Bilirubin / Q000097:blood; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D041781:Jaundice, Obstructive / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D008297:Male; D020551:Pulse Therapy, Drug; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
chemical_list: D000900:Anti-Bacterial Agents; D000964:Antimetabolites, Antineoplastic; D004232:Diuretics; D013256:Steroids; D003841:Deoxycytidine; D001663:Bilirubin; D000093542:Gemcitabine